Navigation Links
Quest Diagnostics to Speak at the Lazard Capital Markets 6th Annual Healthcare Conference
Date:11/13/2009

MADISON, N.J., Nov. 13 /PRNewswire-FirstCall/ -- Quest Diagnostics Incorporated (NYSE: DGX), the world's leading provider of diagnostic testing, information and services, announced that it is scheduled to speak at the Lazard Capital Markets 6th Annual Healthcare Conference in New York City. The presentation is scheduled for Tuesday, November 17, 2009 at 10:55 a.m. Eastern Time.

During the conference, the company will reaffirm its 2009 guidance for revenue growth to approximate 3%, operating income to exceed 18% of revenues, and diluted earnings per share from continuing operations to range from $3.80 to $3.85.

The presentation will be webcast live during the conference and will be available to registered investors on the following site: http://www.wsw.com/webcast/lz6/dgx/ and to the public on www.QuestDiagnostics.com/investor. In addition, the archived webcast will be available one hour after the conclusion of the live event and will remain available until December 17, 2009.

Quest Diagnostics is the world's leading provider of diagnostic testing, information and services that patients and doctors need to make better healthcare decisions. The company offers the broadest access to diagnostic testing services through its network of laboratories and patient service centers, and provides interpretive consultation through its extensive medical and scientific staff. Quest Diagnostics is a pioneer in developing innovative diagnostic tests and advanced healthcare information technology solutions that help improve patient care. Additional company information is available at www.QuestDiagnostics.com'/>"/>

SOURCE Quest Diagnostics
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2

Related medicine news :

1. FDA Questions Safety of Caffeinated Alcoholic Drinks
2. Cholesterol and Cancer: Answers and Some New Questions
3. MDS Inc. and Danaher Corporation Receive Second Request for Information from U.S. Federal Trade Commission for MDS Analytical Technologies Sale
4. Study spotlights efficacy of questionnaire to identify patients at high risk for lung cancer
5. Halloween sex offender policies questioned
6. Your Questions Answered Online About Plastic and Cosmetic Surgery
7. Study questions need for routine intervention in patients with renovascular disease
8. Healthcare Reform, Coverage Changes Highlight Key Questions for Medicare Annual Enrollment Season, Allsup Says
9. Crunch to Host Nationwide Fundraising Event to Support Augies Quest
10. The Pennsylvania Breast Cancer Coalition Announces Request for Applications for Income Tax Check-Off Research Grants
11. Penn study asks, protection or peril? Gun possession of questionable value in an assault
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/23/2014)... A scientist from the University of Exeter has ... for diagnosing a frequently fatal lung disease which ... and bone marrow transplant recipients. , The lateral-flow ... invasive pulmonary aspergillosis, a notoriously difficult to diagnose ... , Invasive aspergillosis is a ...
(Date:7/23/2014)... New York, New York (PRWEB) July 23, 2014 ... that the use of a power morcellator ( http://www.injurybeacon.com/power-morcellator/ ... uterine sarcoma and other cancers throughout a woman’s body, ... on July 22nd in the Journal of the American ... hysterectomy using a power morcellator at 500 U.S. hospitals ...
(Date:7/23/2014)... If past experience is anything to go by, ... get a lot more recognition for their contributions to ... allowing NPs to provide primary care offer nurses more ... relationships with physicians and administrators, compared with colleagues in ... School of Nursing, published in Health Care Management ...
(Date:7/23/2014)... HealthDay Reporter WEDNESDAY, July ... American children and teens look in the mirror and ... reported Wednesday. "Being overweight or obese is associated ... high cholesterol and diabetes," said lead researcher Neda Sarafrazi, ... Control and Prevention,s National Center for Health Statistics. ...
(Date:7/23/2014)... The next episode of “Extreme Weight Loss” Season ... physically fit through childhood and adolescence. After becoming pregnant ... decision to give her son up for adoption. That ... and she punished herself by overeating, gaining nearly 200 ... approach to weight loss transformations, “Extreme Weight Loss” airs ...
Breaking Medicine News(10 mins):Health News:New device detects deadly lung disease 2Health News:Power Morcellator News: Bernstein Liebhard LLP Notes Publication of New Study Confirming Potential for Uterine Morcellation to Spread Undetected Cancer 2Health News:Power Morcellator News: Bernstein Liebhard LLP Notes Publication of New Study Confirming Potential for Uterine Morcellation to Spread Undetected Cancer 3Health News:Power Morcellator News: Bernstein Liebhard LLP Notes Publication of New Study Confirming Potential for Uterine Morcellation to Spread Undetected Cancer 4Health News:New York law offers nurses more recognition, responsibility 2Health News:Many Obese U.S. Kids Think They're Thinner Than They Are 2Health News:Many Obese U.S. Kids Think They're Thinner Than They Are 3Health News:“Extreme Weight Loss”: Cassie’s journey begins at the University of Colorado Anschutz Health and Wellness Center 2
... Autism Speaks, the world,s largest autism science and ... top awards for "Autism Connects", the international student design ... competitors selected by a juried panel demonstrate creative technology ... better connect with the world around them, and allow ...
... News) -- People with allergies and asthma need to take ... Failure to remove contaminated materials and to reduce moisture and ... long-term health risks, according to the American College of Allergy, ... materials quickly lead to the growth of mold, a common ...
... (HealthDay News) -- Children have longer hospital stays if ... language skills, a U.S. study finds. The research, ... of Pediatrics & Adolescent Medicine , included almost 1,300 ... for treatment of infections requiring long-term antibiotics. Among ...
... 2011 The so-called "bad cholesterol" low-density lipoprotein ... shows a Texas A&M University study that casts new light on ... a researcher in the Department of Health and Kinesiology, says the ... health it has been made out to be in recent years ...
... today announced Horizon Pharma,s support of research awards ... through competition and recognition: AGA-Horizon ... $1,000 each to fellows who have submitted abstracts ... (DDW). , AGA-Horizon Pharma Student Abstract ...
... the University of North Carolina at Chapel Hill School of ... developing placenta, have given them the same properties of stem ... The scientific first opens the door for developing novel targeted ... TNBC, this is a highly recurrent tumor that spreads aggressively ...
Cached Medicine News:Health News:Autism Speaks and Core77 Magazine name winners of 'Autism Connects' design challenge 2Health News:Autism Speaks and Core77 Magazine name winners of 'Autism Connects' design challenge 3Health News:Autism Speaks and Core77 Magazine name winners of 'Autism Connects' design challenge 4Health News:Parents' Limited English May Prolong Child's Hospital Stay 2Health News:'Bad' cholesterol not as bad as people think, shows Texas A&M study 2Health News:Horizon Pharma supports fellows and students with AGA Abstract Prizes 2Health News:Normal stem cells made to look and act like cancer stem cells 2
(Date:7/23/2014)... DALLAS , July 23, 2014 ... LLC ("Plaintiff") filed suit in the 116 ... Dallas, Texas , against RegenLab USA, ... Current and Prospective Business Relationships through false ... interference; and, Business Disparagement through libel, ...
(Date:7/23/2014)... 2014 /PRNewswire-iReach/ -- Use of Risk Evaluation and Mitigation ... generic market entry results in $5.4 billion in lost ... analysis by economic consulting firm Matrix Global ... Required by the Food and Drug ... programs are intended to improve drug safety by ensuring ...
(Date:7/23/2014)... 2014 PositiveID Corp. (OTCQB: PSID), based in ... an emerging player in the bio-threat detection market, ... and rapid medical testing. The Company,s proprietary airborne ... Networked Detector), was developed under contract with the ... Technology directorate, and $30 million of contract funding. ...
Breaking Medicine Technology:New Analysis Finds $5.4 Billion In Annual Lost Savings From Strategies Geared Toward Delaying Generic Drug Entry 2PositiveID Analyst Inspection: Emerging Contender in BioThreat Detection - First Ever Revenue Guidance and Backlog Position Company for Increased Visibility and Traction - by SmallCapTraders.com 2
... Requip XL Improved Symptoms in Patients Not Optimally ... "Off" Time by Nearly Two Hours Per Day, ... (NYSE: GSK ) today announced the approval ... for the treatment,of the signs and symptoms of ...
... monotherapy study shows ACTEMRA is first and only biologic to, ... ... treatment -, PARIS, June 13 ... (RA) -- despite treatment with,current therapies -- achieved significant improvements in ...
Cached Medicine Technology:U.S. FDA Approves Requip(R) XL(TM), the First and Only Oral Once-Daily Non-Ergot Dopamine Agonist for Parkinson's Disease 2U.S. FDA Approves Requip(R) XL(TM), the First and Only Oral Once-Daily Non-Ergot Dopamine Agonist for Parkinson's Disease 3U.S. FDA Approves Requip(R) XL(TM), the First and Only Oral Once-Daily Non-Ergot Dopamine Agonist for Parkinson's Disease 4U.S. FDA Approves Requip(R) XL(TM), the First and Only Oral Once-Daily Non-Ergot Dopamine Agonist for Parkinson's Disease 5ACTEMRA(R) (tocilizumab) Significantly Reduces Rheumatoid Arthritis Signs and Symptoms Regardless of Previous Therapy in Two New Global Studies 2ACTEMRA(R) (tocilizumab) Significantly Reduces Rheumatoid Arthritis Signs and Symptoms Regardless of Previous Therapy in Two New Global Studies 3ACTEMRA(R) (tocilizumab) Significantly Reduces Rheumatoid Arthritis Signs and Symptoms Regardless of Previous Therapy in Two New Global Studies 4ACTEMRA(R) (tocilizumab) Significantly Reduces Rheumatoid Arthritis Signs and Symptoms Regardless of Previous Therapy in Two New Global Studies 5ACTEMRA(R) (tocilizumab) Significantly Reduces Rheumatoid Arthritis Signs and Symptoms Regardless of Previous Therapy in Two New Global Studies 6ACTEMRA(R) (tocilizumab) Significantly Reduces Rheumatoid Arthritis Signs and Symptoms Regardless of Previous Therapy in Two New Global Studies 7
Inquire...
... inspects your equipment upon arrival. Our technician then ... provides you with a thorough customer quote. We ... tight budget so well help you prioritize repairs. ... begins., , ISI uses only OEM or widely ...
... Konelab 20XT analyzer is the newest addition ... analyzers and reagents, designed to meet the ... specialty clinical laboratories. The Konelab 20XT analyzer ... 20 and yet improves on the throughput, ...
... The Shandon Coverplate is a plastic device that ... to be immunostained with a minimum amount of ... to fill the gap between the coverplate and ... until the next reagent is dispensed into the ...
Medicine Products: